Published in TB and Outbreaks Week, February 22nd, 1999
Rifampin is the cornerstone of short-course chemotherapy for the treatment of tuberculosis (TB). Rifampin monoresistance (RMR) is less common than resistance to isoniazid alone or resistance to more than one antituberculosis agent.
In this study, L. Sandman and colleagues conducted a retrospective case-control study to identify risk factors for RMR-TB ("Risk Factors for Rifampin-Monoresistant Tuberculosis: A Case-Control Study," American Journal of Respiratory and Critical Care...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.